To explain the beneficial effect of FSH on cardiometabolic risk, a causal relationship between serum FSH and cardiometabolic risk has been suggested through its relation to obesity: Serum FSH level is lower in obese women [34,35] and weight loss elevates FSH levels in overweight post-menopausal women [36]. This evidence concerns the gene BRD2 and obesity disorder.